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Abstract
Background: Inhaled mannitol is a new bronchial provocation test (BPT) developed to improve portability and
standardisation of osmotic challenge testing. Osmotic challenge tests have an advantage over the traditional
methods of measuring airway hyperresponsiveness using methacholine as they demonstrate higher specificity to
identify asthma and thus the need for treatment with inhaled corticosteroids (ICS). The safety and the efficacy of
mannitol (M) as a BPT to measure airway hyperresponsiveness were compared to hypertonic (4.5%) saline (HS)
in people both with and without signs and symptoms of asthma.
Methods: A phase III, multi-centre, open label, operator-blinded, crossover design, randomised trial, with follow-
up. Asthmatics and non-asthmatics (6–83 yr) were recruited and 592 subjects completed the study. Mannitol was
delivered using a low resistance dry powder inhaler and HS was delivered using an ultrasonic nebuliser. The FEV1
was measured 60 seconds after each dose of mannitol (5,10,20,40,80,160,160,160 mg) and after each exposure
to HS (0.5,1.0,2.0,4.0,8.0 minutes). A 15% fall in FEV1 defined a positive test. Adverse events were monitored and
diaries kept for 7 days following the tests.
Results: Mean pre-test FEV1 (mean ± SD) was 95.5 ± 14% predicted. 296 were positive to mannitol (M+) and
322 positive to HS (HS+). A post study physician conducted clinical assessment identified 82.3% asthmatic (44%
classified mild) and 17.7% non-asthmatic. Of those M+, 70.1% were taking ICS and of those mannitol negative (M-),
81.1 % were taking ICS. The % fall in FEV1 for mannitol in asthmatics was 21.0% ± 5.7 and for the non-asthmatics,
5.5% ± 4.8. The median PD15 M was 148 mg and PD15 HS 6.2 ml. The sensitivity of M to identify HS+ was 80.7%
and the specificity 86.7%. The sensitivity of M compared with the clinical assessment was 59.8% and specificity
95.2% and increased to 88.7% and 95.0% respectively when the M- subjects taking ICS were excluded. Cough was
common during testing. There were no serious adverse events. The diarised events were similar for mannitol and
HS, the most common being headache (17.2%M, 19%HS), pharyngolaryngeal pain (5.1%M, 3%HS), nausea (4.3%M,
3%HS), and cough (2.2%M, 2.4%HS).
Conclusion: The efficacy and safety of mannitol was demonstrated in non-asthmatic and clinically diagnosed
asthmatic adults and children.
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Background
The bronchial provocation test that uses an aerosol of
hypertonic (4.5%) saline as an indirect stimulus was
developed over a number of years by Anderson and others
in Australia [1-4]. The test subsequently became known as
the hypertonic saline (HS) test. In epidemiology it was
first used in a study in children with exercise as a compa-
rator challenge [5]. The HS test has now been used safely
in both adults and children for a wide variety of studies for
20 years [6-9]. A 15% reduction in forced expiratory vol-
ume in one second (FEV1) is used to define abnormality
[10]. The dose of 4.5% saline to provoke this fall in FEV1
(PD15) is the index used to express the airway sensitivity
to this stimulus or the airway hyperresponsiveness (AHR)
[10]. There are some technical difficulties with the HS test
that preclude it from being a common operating standard
for investigators [4].
In order to overcome some of these problems a dry pow-
der preparation of mannitol was developed to provide a
more simple form of osmotic challenge [11]. The studies
using dry powder mannitol demonstrated that it had a
very similar profile to HS [12]. Further those subjects
responsive to other challenge tests that acted 'indirectly' to
cause airways to narrow e.g. exercise, eucapnic voluntary
hyperpnea [13], and adenosine monophosphate [14],
were also responsive to mannitol. The major advantage in
using provoking stimuli that act 'indirectly' to cause air-
ways to narrow is the high specificity for identifying the
type of AHR that is altered by drugs used in the treatment
of asthma [15,16], and inhaled corticosteroids in particu-
lar. Sensitivity to mannitol is reduced or even totally
inhibited following chronic administration of inhaled
corticosteroids (ICS) [17], therefore allowing monitoring
of therapy [18]. Further, in subjects whose asthma is well
controlled with ICS, response to mannitol has been used
to predict exacerbations following back titration of steroid
dose [19]. In these respects challenge with mannitol is dif-
ferent from challenge with methacholine. Whilst respon-
siveness to methacholine can be reduced 1 to 2 doubling
doses in response to treatment with inhaled steroids, most
patients still record a positive response [20-22] and this
agent has not been useful to guide for titration of steroid
dose [23].
We aimed to determine the efficacy and safety profile of a
commercial preparation of dry powder mannitol in sub-
jects with and without signs and symptoms of asthma. A
phase III, multi-centre, open label, operator-blinded,
crossover design, randomised trial, with follow-up was
performed comparing the airway response to mannitol
with the HS test and a standard clinical assessment of
asthma.
Methods
Study design
The study was an operator blinded, randomised, crossover
comparator study. At Visit 1, after entry and randomisa-
tion to determine the order of each challenge, each subject
answered a questionnaire, had skin prick tests for aeroal-
lergens then underwent the first challenge. The second
challenge was scheduled one week later at Visit 2 and the
study was complete a week after the second challenge at
Visit 3, when each subject returned for a measurement of
spirometry. The respiratory scientist conducting the initial
challenge was blinded to the subject's asthma status and
the respiratory scientist conducting the reciprocal chal-
lenge was blinded to the results of the initial challenge
and the asthma status of the subject. The respiratory phy-
sician was blinded to the results of the mannitol challenge
and the identity of the subject when determining the
asthma status of the subject.
The protocol was approved by the Ethics Review Commit-
tee of each participating hospital. The trial was carried out
under the Clinical Trial Notification scheme of the Thera-
peutic Goods Administration of Australia (CTN Nos
2003/240, 035/2003).
Table 1: Demographics of populations
Safety Population (n = 646) Efficacy Population (n = 592)
Age (yrs) 34.8 (6 to 83) 34.7 (6 to 83)
Gender 47% M: 53% F 46% M: 54% F
Race 91% Caucasian 91% Caucasian
BMI (kg/m2) 25.5 (0.6) 25.5 (0.6)
Height (cm) 164.2 (14.0) 164.3 (13.9)
Weight (kg) 70.2 (21.6) 70.1 (21.6)
Asthmatics (n) 551 505
FEV1 (L) 3.0 (0.9) 3.0 (0.9)
% Predicted FEV1 95.0 (14.5) 95.5 (14.7)
Non-asthmatics (n) 95 91
FEV1 (L) 3.2 (0.9) 3.2 (0.9)
% Predicted FEV1 94.6 (14.1) 95.2 (14.4)Respiratory Research 2005, 6:144 http://respiratory-research.com/content/6/1/144
Page 3 of 12
(page number not for citation purposes)
Subjects
Of six hundred and fifty-four subjects 6 years of age and
above recruited from the local community and from pul-
monary function clinics, 646 completed at least one chal-
lenge and were included in the population that could be
analysed for the safety analysis (Table 1) (Figure 1). Of
these, 592 subjects (466 adults, 126 children 6–83 yrs)
completed both challenge tests and were used for the effi-
cacy analysis.
The asthmatic subjects were required to have active signs
and symptoms of asthma according to the National
Asthma Council of Australia Asthma Management Hand-
book Guidelines [24]. The non-asthmatic subjects were
required never to have had a clinical diagnosis of asthma
or experienced signs and symptoms suggestive of asthma.
All subjects gave informed consent to participate in this
study in accordance with ICH GCP guidelines and local
regulatory requirements.
Subjects were required to have a baseline FEV1 greater
than 70% of normal predicted values for asthmatic sub-
jects OR greater than 80% of normal predicted values for
non-asthmatic subjects. No subject was to have an active
upper or lower respiratory tract infection severe enough to
require a medical consultation or any other acute or
chronic pulmonary disorder including:- cystic fibrosis,
chronic obstructive pulmonary disease, bronchiectasis,
chronic bronchitis, emphysema, tuberculosis, and carci-
noma. Further, subjects with current uncontrolled hyper-
tension or known aortic aneurysm, myocardial infarction
or cerebral vascular accident in the last six months, or ocu-
lar or abdominal surgery in the three months prior to
enrolment were excluded from the study.
Flow chart showing the progression of subjects through the study Figure 1
Flow chart showing the progression of subjects through the study.
Protocol Deviations
n=1 3
Failed to withhold
asthma meds = 2
Failed to complete
mannitol challenge = 4
Failed to complete
saline challenge = 3
Premature termination
of challenge due
to rounding error = 3
Invalid challenge data = 1
Randomised
n = 654
Safety/ITT Population
n = 646
Subjects withdrawn prior to
receiving challenge
n=8
Group A
Mannitol
1st Challenge
n = 319
Group B
Saline
1st Challenge
n = 327
Participated in
both challenges
n = 309
Participated in
both challenges
n = 308
Per Protocol population
n = 592 (PD15)
Withdrew prior to
participating in both
challenges
n=1 0
Adverse event = 4
Subject decision = 2
Lost to follow-up = 3
Other = 1
Protocol Deviations
n=1 2
Failed to withhold
asthma meds = 1
Failed to complete
mannitol challenge = 7
Failed to complete
saline challenge = 1
Premature termination
of challenge due
to rounding error = 3
Withdrew prior to
participating in both
challenges
n=1 9
Adverse event = 3
Subject decision = 3
Lost to follow-up = 3
Violation of criteria = 3
Physician decision = 2
Other = 5Respiratory Research 2005, 6:144 http://respiratory-research.com/content/6/1/144
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No subject could be breast feeding or pregnant, or have
participated in another trial in the previous 4 weeks, be
related to a study investigator, or have a known intoler-
ance to mannitol or salbutamol. No subject was to have a
previous admission to Intensive Care for asthma in the
two years prior to study entry, and no subject could be tak-
ing oral / parenteral corticosteroids in the two weeks prior
to study enrolment.
All subject were required to be able to perform repeatable
spirometry according to American Thoracic Society (ATS)
criteria [25], and to withhold strenuous exercise and
smoking for 6 hr; caffeine, short acting bronchodilators
(SABA), sodium cromoglycate and nedocromil sodium
for 8 hr; inhaled corticosteroids (ICS) alone and combina-
tion with long acting bronchodilators (LABA), and short
acting anti-cholinergics for 12 hr; theophylline for 24 hr;
long acting anti-cholinergics and anti-histamines for 72
hr; and leukotriene antagonists for 4 days. Subjects were
encouraged to keep their dose of inhaled corticosteroids
constant over the course of the study. Visit 2 pre-challenge
FEV1 was required to be within 10% of that at Visit 1.
Challenges were performed at the same time of day ± 2
hours.
Questionnaires
Two questionnaires were carried out, one investigating
respiratory history over the preceding 12 months and
based on the International Study of Asthma and Allergies
in Childhood (ISAAC) Steering Committee Phase 1 and 2
modules [26]. The other was an investigator designed
questionnaire about symptoms for the week immediately
prior to each visit. The symptom questions included fre-
quency and severity of cough (during the day or night)
and wheeze, bronchodilator use, number of days troubled
by breathing and number of days that symptoms inter-
fered with work or school activities.
Each subject was issued with a study diary at Visit 1 and
requested to complete the diary every day up to their third
visit when they handed it to the investigator. The diary
was a record of adverse events, respiratory symptoms and
concomitant medications. The investigator was responsi-
ble for reviewing the diary for completeness at the final
visit.
Mannitol challenge
Dry powdered mannitol (Aridol™) was supplied in kit
form (Pharmaxis Ltd., NSW Australia) and contained one
empty capsule (0 mg), 2 × 5, 2 × 10, 2 × 20, and 18 × 40
mg capsules. The dry powder device used for inhalation
was the Osmohaler™ (RS-01, Plastiape™, Italy), a single
capsule device with a low inspiratory resistance. The man-
nitol challenge required the FEV1 to be measured 60 sec-
onds after each mannitol dose (5,10,20,40,80,160,160,
160 mg). If the FEV1 fell by = 10% on any one dose then
that same dose was repeated.
The challenge started with the empty capsule. This was
loaded into the device and punctured by the investigator.
The subjects were asked to inhale from the device from
near to functional residual capacity to near to total lung
capacity and to hold their breath for 5 seconds. Subjects
were encouraged to keep a nose clip on for 10 seconds
after inhalation and then exhale through their mouth to
minimise deposition in the nasopharynx. In addition to
providing the baseline FEV1, the inclusion of the 0 mg
capsule demonstrated the sound and use of the device to
the subject. Hearing the capsule rotating indicated that
sufficient inspiratory flow had been achieved and that it
was positioned correctly in the chamber. Sixty seconds
after inhalation of the 0 mg capsule the FEV1 was meas-
ured and two repeatable values were obtained and
recorded. The highest of these values was taken as the
baseline FEV1 and was used to calculate the target FEV1
value that indicated a 15% fall in response to the manni-
tol challenge. This value was calculated immediately after
the administration of the 0 mg capsule.
The first dose of mannitol (5 mg) was administered, and
sixty seconds later the FEV1 was measured to obtain two
repeatable FEV1 values. This procedure was repeated for
each dose step until a 15% fall in FEV1 was achieved or the
cumulative dose of 635 mg had been administered. At
each dose step, oxygen saturation and cough severity were
recorded.
Hypertonic (4.5%) saline challenge
The initial exposure time for inhaling the 4.5% saline was
for 30 sec, then 1 min, 2 min, 4 min, and 8 min. The FEV1
was measured at least twice 60 seconds after each expo-
sure time. The subjects wore a nose clip and were encour-
aged to breathe normally through a two-way non-
rebreathing valve. If the fall in FEV1 was = 10% on any one
exposure time the same exposure time was repeated. The
ultrasonic nebuliser was required to have an output of at
least 1.5 ml/min. After each exposure time, oxygen satura-
tion and cough severity were recorded.
Calculation of responses
The highest value of 2 repeatable FEV1 measurements
made after each dose was used in the calculation for the %
fall in FEV1. The dose of mannitol (mg) or saline (ml) to
provoke a 15% fall in FEV1 (PD15) was calculated by linear
interpolation from the curve relating the % fall in FEV1.
For mannitol this was from the post 0 mg capsule baseline
value for FEV1 to the cumulative dose of mannitol deliv-
ered (e.g. 5 mg, 15 mg, 35 mg, 75 mg, 155 mg, 315 mg,
475 mg, 635 mg). For saline, the amount of aerosol deliv-
ered per minute was calculated by dividing the totalRespiratory Research 2005, 6:144 http://respiratory-research.com/content/6/1/144
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amount delivered by the time of delivery (e.g. 28 ml in
15.5 min = 1.81 ml/min). The dose was expressed cumu-
latively over time.
The response dose ratio (RDR) was calculated by taking
the final % fall in FEV1 recorded and dividing it by the
cumulative dose of mannitol or saline administered to
induce that % fall. For calculation of the RDR a value of
0.1 was used for those having 0% fall in FEV1.
Efficacy was analysed using sensitivity and specificity of
the mannitol challenge with respect to the 4.5% saline
challenge and the clinical assessment. Subjects were con-
sidered positive to a test if at least a 15% reduction in FEV1
from baseline occurred. Subjects who reached the end of
a challenge with <15% reduction in FEV1 were considered
to have a negative response.
Recovery
On completion of the challenge, subjects with a 15% or
more percentage fall in FEV1 received 200 mcg of the beta2
adrenoceptor agonist salbutamol via a Volumatic™ spacer.
If the FEV1 had not returned to within 5% of the baseline
FEV1 in 15 minutes a second dose of salbutamol was
administered.
Vital signs for challenge
Vital Signs measured were sitting blood pressure, oxygen
saturation by pulse oximetry (SpO2), respiratory rate, and
heart rate measured at the beginning of the challenge, on
immediate completion of the challenge (before adminis-
tration of salbutamol in those with a positive response),
and 15 minutes after challenge.
Clinical assessment
All subjects were designated asthmatic or non-asthmatic
based on Respiratory History Questionnaire, Respiratory
Symptom Questionnaire, spirometry results, concomitant
medications and the result of the 4.5% saline challenge.
The subjects were not interviewed by the Respiratory Phy-
sicians who were blinded to the identity of the subjects.
Subjects with a diagnosis of asthma were graded by the
physician according to the GINA guidelines [27].
Statistical methods
The sample size of 600 was primarily based on safety and
chosen to be large enough to document the adverse event
profile of dry powder mannitol. In the total population, at
least 100 were required to be aged 6 × 17 years, 10 of these
being non- asthmatics. To compare the adverse events for
mannitol and HS 2 × 2 contingency tables were used. Effi-
cacy was analysed in terms of response to each challenge
(mannitol and saline) in subjects that had both mannitol
and HS challenge, and in terms of the investigator's clini-
cal assessment or the classification of asthmatic/sympto-
matic or non-asthmatic at study entry. The challenge
results are represented as: M+/M- = positive/negative test
result with mannitol, S+/S- = positive/negative test result
with HS, A+/A- = asthmatic-symptomatic/non-asthmatic
at study entry, C+/C- = asthmatic/non-asthmatic by physi-
cian's clinical diagnosis at Visit 3. Cross-tabulations were
performed to create 2 × 2 tables of the number of subjects
within each of four cells for each challenge. In the analysis
of mannitol vs HS, the four cells comprised of those pos-
itive to both challenges (M+, S+), those negative to both
challenges (M-, S-), those positive to mannitol and nega-
tive to HS (M+, S-), and those negative to mannitol and
positive to HS (M-, S+). Sensitivity was calculated as the
probability of a positive test result with mannitol, given a
positive HS result (Pr(M+ | S+)), i.e. the number of sub-
jects positive to mannitol out of the total number of sub-
jects positive to HS. Specificity was calculated as the
probability of a negative test result with mannitol, given a
negative HS result (Pr(M- | S-)), i.e. the number of sub-
jects negative to mannitol out of the total number of sub-
jects negative to HS.
A cross over logistic regression analysis was performed
using the results of the mannitol and HS challenges to
examine sequence effects, and another to look for study
site differences. A cross over regression analysis was also
performed to investigate differences between mannitol
and HS in the change from baseline (0 mg for mannitol,
pre challenge for HS) to end of challenge for the vital sign
parameters: systolic and diastolic blood pressure, oxygen
saturation, heart rate and respiratory rate.
Results
All the subjects classed as asthmatics at entry had an estab-
lished history of asthma, with most having symptoms
before 19 years of age. Asthmatic subjects had normal
FEV1 values and there was no difference compared to the
non-asthmatics (Table 1). A total of 646 subjects com-
pleted at least one challenge with 627 exposed to manni-
tol and 636 to HS. The mean dose of mannitol
administered was 433.6 ± 237.2 mg, with the mean for
subjects with a positive mannitol test being 239.0 ± 185.0
mg. As expected, the mean ± SD cumulative dose for a
negative mannitol test was 635 ± 0.9 mg. For the HS chal-
lenge, the mean dose ± SD for all subjects was 21.6 ± 13.5
ml, 12.9 ± 11.3 ml in subjects with a positive HS challenge
and 32.4 ± 6.3 ml for subjects with a negative challenge.
The output of the ultrasonic nebuliser ranged from 0.24 to
4.4 ml/min, with a mean of 2.1 ± 0.5 ml/min.
In the efficacy population (n = 592) that included both
asthmatics and non-asthmatics, the severity of symptoms
using the questionnaire specific to the week prior to com-
mencement of the study revealed that there were 39.0%
(n = 231) with wheeze, 32.8% (n = 194) with troubleRespiratory Research 2005, 6:144 http://respiratory-research.com/content/6/1/144
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breathing, and 11.3% (n = 67) who had respiratory symp-
toms that interfered with normal activities. There were
45.2% (n = 292) who had daytime cough that lasted for a
mean ± SD of 4.0 ± 2.5 days, with 82.5% (n = 241) stating
that it was only occasional. Cough at night time was
reported by 31.6% (n = 187) and 49.5% (n = 293)
reported using a reliever puffer in the past week. Only
6.3% (n = 37) reported having a cold or flu in the past
week. There were 78.4% taking at least one medication for
asthma. Of those assessed as asthmatics at entry 27.7 %
were taking ICS alone and 38.5% in combination with a
LABA, 15.6% were taking only a SABA and 3 subjects tak-
ing only a LABA. Only 1.7% were taking leukotriene
antagonists, 4.6% were taking an anti-cholinergic and
2.2% were taking sodium cromoglycate.
As designated by the clinical assessment, 82.3% (n = 487)
of the efficacy population (n = 592) were asthmatic and
17.7% (n = 105) were non-asthmatic. Of the 378 adult
asthmatic subjects, 50.5% (n = 191) were classed as mild,
39.9% (n = 151) were classed as moderate, and 9.5% (n =
36) as severe (Table 2). For the 109 paediatric asthmatic
subjects, 22.0% (n = 24) were classed as infrequent epi-
sodic, 17.4% (n = 19) as frequent episodic, and 60.6% (n
= 66) were classed as persistent.
Of the 592 subjects 50.0% (n = 296) were positive to the
mannitol challenge and 54.4% (n = 322) positive to HS.
For those who were positive the maximum mean % fall in
FEV1 was similar for both mannitol (21.0% ± 5.7 (range:
15.0–45.5)) and for HS (21.3% ± 5.9 (range:15.0–48.62))
and there was a relationship between maximum % fall in
FEV1 to both challenges (rp = 0.62, p < 0.001). The maxi-
mum mean % fall in FEV1 in children less than 12 years of
age was 21.1% ± 6.0 (range:15.85 × 40.30) for mannitol
and 22.0% ± 6.4 (range:16.34–48.62) for HS. Only 14
subjects recorded a maximum fall in FEV1 greater than
30% and the majority had a fall between 15% and 25%
(Figure 2). For hypertonic saline 18 subjects recorded a
fall of 30% or more.
The geometric mean (95% CI) for PD15 was 112.20 mg
(97.72 mg, 128.82 mg) for mannitol and 5.01 ml, (4.27
ml, 5.75 ml) for HS. The median PD15 for mannitol was
148.1 mg and for HS it was 6.2 ml. There was a moderate,
though statistically significant, correlation between log
transformed PD15 between mannitol and HS (r = 0.53, p
< 0.0001). Those adults with a classification of mild
asthma had a PD15 for mannitol that was significantly dif-
ferent from those classed as having moderate and severe
asthma (Table 2). There was a trend for those children
with episodic asthma to have higher PD15 values however
there was no significant difference between the responses
and their clinical severity classification.
The maximum mean % fall in FEV1 from baseline for sub-
jects who were clinically assessed as non-asthmatic was
5.5% ± 4.8 after mannitol and 5.4% ± 4.9 after HS. The
median (range) RDR for those with a negative challenge
The percent reduction in FEV1 from baseline in relation to  the total dose of mannitol for the 592 subjects with and with- out symptoms of asthma of which 292 were positive to the  mannitol challenge Figure 2
The percent reduction in FEV1 from baseline in relation to 
the total dose of mannitol for the 592 subjects with and with-
out symptoms of asthma of which 292 were positive to the 
mannitol challenge.
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Table 2: Clinical classification based on GINA guidelines of all asthmatics, including those who returned a positive challenge
ADULTS Mild Moderate Severe
n (Total) 191 151 36
n (with PD15)8 0 1 0 7 3 5
GeoMean PD15 mg (95% CI) 186 (148, 233) 78* (58, 106) 56* (36, 98)
CHILDREN Infrequent Episodic Frequent Episodic Persistent
n (Total) 24 19 66
n (with PD15)1 8 1 4 5 4
GeoMean PD15 mg (95% CI) 113 (59, 217) 117 (73, 187) 67 (46, 99)
* p < 0.001 compared with mildRespiratory Research 2005, 6:144 http://respiratory-research.com/content/6/1/144
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was 0.0075 (0.0–0.0317) for mannitol and 0.15 (0.0–
0.70) for HS. For the group who were non-asthmatic the
RDR geometric mean (95% CI) for mannitol was 0.0029
(0.002, 0.004) and for the HS was 0.11 (0.085, 0.139).
The highest proportion (28.7%) of subjects achieving a
positive mannitol challenge result did so in the cumula-
tive dose range of >155 × 315 mg, 18.2% were positive in
the >75 × 155 dose range and 16.2% in the >35 × 75 dose
range (Figure 3). Eighty percent of those who achieved a
fall of 15% or more did so in a dose = 315 mg (10 cap-
sules).
Nineteen (3.0%) subjects had repeat mannitol doses,
89.5% (n = 17) of whom went on to achieve a PD15, the
remaining two subjects having maximum falls in FEV1 of
14.55% and 14.85%. Thirty-six recorded a PD15 to manni-
tol but did not achieve a PD15 to HS, while 62 achieved a
PD15 to HS but not to mannitol. There was no significant
sequence effect (p= 0.2) and no significant difference
between the treatment order or the study site for mannitol
and HS responses.
The mean ± SD time taken for a positive mannitol chal-
lenge was 17.3 ± 7.09 minutes and for HS was 15.0 ± 9.1
minutes. For a negative challenge the mean ± SD for man-
nitol was 26.4 ± 6.1 minutes and for HS it was 27.3 ± 3.6
minutes. It should be noted that this included the time
taken to complete the post challenge measurement of the
vital signs.
For subjects with a positive challenge test, the time to
recover to 95% baseline FEV1 was similar for both manni-
tol and HS, being 19.4 ± 8.8 minutes and 19.3 ± 8.7 min-
utes respectively. The maximum recovery time was 65
minutes for mannitol and 79 minutes for HS. There were
344 (54.9%) subjects who received 200 mcg of salbuta-
mol after the mannitol challenge, and 370 (58.2%) after
HS. A second salbutamol dose of 200 mcg was given to 46
(7.3%) subjects after mannitol and 38 (6.0%) after HS,
with additional bronchodilator given in 6 (1.0%) subjects
following the mannitol challenge and 2 (0.3%) following
HS.
There were 535 (85.3%) subjects who experienced cough
during the mannitol challenge and 468 (73.5%) during
the HS challenge. The mean cumulative dose at which
cough was first reported was 62.7 mg for mannitol and
5.07 ml for HS. The majority of subjects, 70.8% for man-
nitol and 64.8% for HS, experienced occasional cough
causing no delay in administering the next dose. Frequent
cough causing a delay in the challenge was noted in 83
(13.2%) subjects during the mannitol challenge and 51
(8%) subjects during HS. There were 8 (1.3%) subjects
during mannitol and 5 (0.8%) during HS who were noted
to have a cough severe enough to stop the challenge
although 2 and 4 respectively did record a 15% fall in
FEV1 at the time they were stopped.
There were 14 (2.2%) subjects who commenced but did
not complete the mannitol challenge and 9 (1.4%) sub-
jects who did not complete the HS challenge. The most
frequent causes of an incomplete challenge were incorrect
calculation of the target 15% reduction in FEV1 (which
resulted in premature termination of the challenge) and
cough (see above).
The sensitivity and specificity for mannitol to identify
responsiveness to HS and for the clinical diagnosis are
given in Table 3. As expected the sensitivity for mannitol
to identify a clinical diagnosis of asthma was lower due to
many asthmatics taking ICS, however the specificity
remained high. The sensitivity in children (<12 yrs) was
85.5% (95% CI: 76.1, 94.8) and the specificity was 68.4%
(95% CI: 47.5, 79.0).
Subjects diagnosed with asthma who were using ICS
(either alone or in combination with a beta2 agonist) were
divided into mannitol positive and negative. Of the 291
subjects mannitol positive, 204 (70.1 %) had been using
ICS prior to the first challenge; of the 196 subjects nega-
tive to mannitol, 159 (81.1%) had been using ICS prior to
the first challenge. As an exploratory analysis, the subjects
who were mannitol negative and taking ICS before the
study were removed from the analysis of sensitivity and
specificity for mannitol with respect to the clinical assess-
ment and there was an improvement in sensitivity
(88.7%) and specificity (95.0%).
Number of subjects with a 15% fall in FEV1 to mannitol at  each dose interval Figure 3
Number of subjects with a 15% fall in FEV1 to mannitol at 
each dose interval.
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Adverse events
In the 7 days following each challenge, 45.3% (n = 284)
reported adverse events after mannitol and 44.7% (n =
284) after the HS. Applying the MedDRA classifications
(Table 4), the nervous system was most frequently
affected, followed by in decreased order of incidence; res-
piratory, thoracic and mediastinal disorders, gastrointesti-
nal disorders, infections and infestations. There was no
statistically significant difference in the incidence between
these events for either challenge (p = ns). The most com-
mon related events in the 7 days following the mannitol
challenge were headache, reported in 8.3% (n = 52), fol-
lowed by pharyngolaryngeal pain in 3.5% (n = 22) and
nausea in 2.4% (n = 15) of subjects. Headache was more
prevalent in those negative to mannitol (13.6%) com-
pared to those with a positive mannitol challenge (3.0%).
Severe adverse events as defined by extremely distressed or
unable to do usual activities were reported in 6.2% (n =
39) after mannitol and 4.7% (n = 30) after HS. The most
common were respiratory, thoracic and mediastinal disor-
ders reported in 2.1% (n = 13) after the mannitol and
1.4% (n = 9) after HS. Nervous system disorders were
reported in 1.6% (n = 10) after mannitol and 1.9% (n =
12) after HS. These were headache in 1.3% (n = 8) after
mannitol, and 1.1% (n = 7) after HS, followed by cough
or aggravated cough in 0.8% (n = 5) after mannitol, and
0.3% (n = 2) after HS.
Withdrawal from the study due to adverse events occurred
in four (0.6%) after the mannitol, and three (0.5%) after
the HS. There were no statistically significant carryover
effects for any of the baseline, end challenge, or recovery
values for systolic and diastolic blood pressure, oxygen
saturation, heart rate, and respiratory rate, either at the
end of challenge or at recovery (p > 0.2) (Table 5).
The incidence of respiratory symptoms as reported by
symptom diary in the week following mannitol was very
similar to that following HS and the duration and severity
of these symptoms were very similar in both challenges
(Table 6). There were 41.8% (n = 259) who experienced
new or unusual symptoms in the week following the man-
nitol challenge, with a similar incidence, 41.1% (n = 257)
after HS. Changes to existing medication regimens, or use
of new medications were reported in the questionnaire in
26.7% (n = 165) after mannitol and 29.4% (n = 184) after
HS.
Discussion
All asthmatics had an established history of asthma with
good lung function that was similar to that seen with the
non-asthmatics. Further, reliever bronchodilator was
taken in 51.3% in the week prior to commencement of the
study, however only 11.9% reported symptoms interfer-
ing with normal activity. The majority of adult asthmatic
subjects, classified using GINA guidelines, had mild dis-
ease and most probably represent the population to be
assessed using a bronchial provocation test, i.e. those with
good lung function and mild symptoms.
The median doses of mannitol (148 mg) and HS (6.2 ml)
to cause a 15% fall in FEV1 were similar to those that have
previously been identified as the cut-off point between
moderate and mild AHR to mannitol (155 mg) and HS
(6.1 ml) [10]. Thus 50% of the asthmatic subjects were in
the mild range of AHR to these agents and this was con-
sistent with the cohort's treatment and symptom profile,
i.e. symptoms less than once per week.
These results demonstrate the safety of the inhaled man-
nitol challenge to identify AHR. There were no serious
adverse events recorded. There was no difference in the
overall safety profile demonstrated by a similar adverse
event profile between mannitol and HS. The low inci-
dence of headache, the most frequent complaint after
both challenges, was likely to be a direct result of the chal-
lenge procedure. Headache was more prevalent in those
with a negative mannitol challenge and likely due to the
larger number of forced expiratory manoeuvres required
compared to those with a positive challenge.
The mean maximum fall in FEV1 was similar for both the
mannitol and HS challenges and close to the target FEV1
of 15%. Relative to the potential fall in FEV1 that can occur
following challenges such as exercise, this is a moderate
Table 3: Sensitivity and specificity of response to mannitol compared to hypertonic saline and a clinical assessment of asthma (Clinical 
Dx)
Sensitivity (95% CI) Specificity (95% CI)
Mannitol vs Hypertonic Saline 80.7 (76.4, 85.1) 86.7 (82.6, 90.7)
Mannitol vs Clinical Dx 59.8 (55.4, 64.2) 94.5 (89.9, 99.2)
Hypertonic Saline vs Clinical Dx 65.1 (60.9, 69.3) 95.2 (91.1, 99.3)
Excluding all taking ICS
Mannitol vs Clinical Dx 70 (62.1, 78.2) 95 (90.7, 99.3)
Excluding M-ve taking ICS
Mannitol vs Clinical Dx 89 (85.3, 92.1) 95 (90.7, 99.3)Respiratory Research 2005, 6:144 http://respiratory-research.com/content/6/1/144
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decrease in FEV1. Few subjects had a fall in FEV1 greater
than 30%, a value that is frequently attained when testing
with exercise or with dry air as the stimulus [28,29]. Only
two subjects responded positively to the initial mannitol
dose of 5 mg and the falls in FEV1 were 15% and 26%.
Twelve subjects had a PD15 to hypertonic saline = 1.0 ml
which is equivalent to a 30 sec exposure to the aerosol.
Only two of the 19 subjects who had a between dose fall
in FEV1 of >10% failed to achieve a PD15 and for both
these subjects the maximum fall achieved was greater than
14.5%. Thus a fall in FEV1 of 10% between doses of man-
nitol should also be considered as a positive challenge
and signal an end to the challenge procedure. The PD15
can then be extrapolated from the recorded response at
the 10% fall.
Bronchoconstriction provoked by other challenge tests
may be accompanied by significant reductions in SpO2,
e.g. exercise challenge [28]. However the reduction in
SpO2 during the mannitol challenge was small and was
probably of clinical significance in only 3 subjects (i.e.,
>3%). There were only small and clinically insignificant
changes in blood pressure, heart rate, and breathing fre-
quency after challenge. This is in contrast to a challenge
with exercise that can be associated with substantial
changes in blood pressure, heart rate, and breathing fre-
quency [28]. The insignificant changes in vital signs are
relevant when choosing a test for the assessment of airway
responsiveness in older subjects.
Cough is a recognised aspect of both the mannitol and HS
challenges [30]. The majority of subjects (>85%) had
either an occasional cough or no cough in response to the
mannitol challenge. This finding is consistent with the
mild severity of disease in the majority of asthmatic sub-
jects and the high proportion taking ICS. Severe cough
was infrequent, occurring in only 1.3% of subjects during
the mannitol challenge. For 8 subjects the cough was too
severe to continue the challenge.
Table 4: Adverse events (AE) starting on the same day & between 1 & 7 days after challenge by MedDRA System Organ Class & 
Preferred Term (Safety population)
System Organ Class Preferred Term AE starting on same day as AE starting between 1 & 7 days after
Mannitol challenge Hypertonic Saline
challenge
Mannitol challenge Hypertonic Saline
challenge
n 627 (%) 636 (%) 627 (%) 636 (%)
Any 102 (16.3) 84 (13.2) 217 (34.6) 228 (35.8)
Eye disorders 3 (0.5) 1 (0.2) 8 (1.3) 5 (0.8)
Gastrointestinal disorders 15 (2.4) 15 (2.4) 46 (7.3) 29 (4.6)
Abdominal pain upper 1 (0.2) 3 (0.5) 11 (1.8) 6 (0.9)
Diarrhoea NOS 1 (0.2) 1 (0.2) 7 (1.1) 3 (0.5)
Nausea 7 (1.1) 9 (1.4) 20 (3.2) 9 (1.4)
General disorders and 
administration
10 (1.6) 6 (0.9) 22 (3.5) 13 (2.0)
Infections and infestations 2 (0.3) 4 (0.6) 26 (4.1) 40 (6.3)
Nasopharyngitis 1 (0.2) 3 (0.5) 8 (1.3) 16 (2.5)
Upper respiratory tract infect 1 (0.2) 6 (1.0) 11 (1.7)
Injury, poisoning and 
procedural complications
3 (0.5) 14 (2.2) 11 (1.7)
Investigations 4 (0.6) 4 (0.6) 1 (0.2) 2 (0.3)
Metabolism and nutrition 
disorders
1 (0.2) 2 (0.3)
Musculoskeletal and 
connective tissue disorders
1 (0.2) 3 (0.5) 24 (3.8) 14 (2.2)
Back pain 1 (0.2) 6 (1.0) 3 (0.5)
Nervous system disorders 46 (7.3) 38 (6.0) 87 (13.9) 101 (15.9)
Headache NOS 38 (6.1) 32 (5.0) 78 (12.4) 92 (14.5)
Respiratory, thoracic and 
mediastinal disorders
40 (6.4) 21 (3.3) 48 (7.7) 61 (9.6)
Asthma aggravated 1 (0.2) 3 (0.5) 6 (1.0) 5 (0.8)
Cough 8 (1.3) 6 (0.9) 6 (1.0) 8 (1.3)
Pharyngolaryngeal pain 16 (2.6) 5 (0.8) 16 (2.6) 13 (2.0)
Rhinorrhoea 4 (0.6) 9 (1.4) 9 (1.4)
Throat irritation 7 (1.1) 1 (0.2) 1 (0.2)
Skin and subcutaneous tissue 
disorders
1 (0.2) 4 (0.6) 10 (1.6) 11 (1.7)Respiratory Research 2005, 6:144 http://respiratory-research.com/content/6/1/144
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The sensitivity of mannitol to identify subjects with AHR
to HS was lower than expected, given the results of an ear-
lier study [11]. The majority of subjects (52 of 62) who
were negative to mannitol and positive to HS had AHR to
HS within the mild range (PD15>6.1 ml). The reason for
the discrepancy is not clear from the results but several
explanations can be postulated. One explanation is that
the HS is administered with tidal breathing whereas man-
nitol is given with an inhalation to total lung capacity.
Cockcroft et al [31] have reported a similar discrepancy
between methacholine responsiveness in mild subjects
when the dosimeter technique that uses a deep inspira-
tion is compared with the tidal breathing technique. Alter-
natively, it may relate to a higher than usual output of the
nebulisers delivering the 4.5% saline. It would be
expected that if too much fluid deposits in the airways it
could amplify the airway narrowing effect of a small
amount of smooth muscle contraction, thereby causing a
false positive response [32]. Other possible reasons
include subjects becoming more compliant with their
medication after their initial challenge, and that the
period between last medication and the challenge was var-
iable, although a minimum of 12 hr was required.
It is likely that the relatively high number of negative chal-
lenges in subjects with asthma is largely due to the fact
that such a high proportion of the subjects were using ICS
and therefore their airway inflammation was well control-
led. Airway sensitivity to mannitol is reduced or inhibited
by treatment with ICS [17,18], a feature that allows it to
be used for monitoring therapy [33]. The use of ICS
largely explains the discrepancy between the sensitivity to
both challenge tests and the clinical assessment, which
was made on information that included medications
taken by the subject. Of the total group of diagnosed asth-
matic subjects, 75% were taking ICS.
Based on earlier studies, the sensitivity of the mannitol
challenge would have been expected to be higher and, up
to 95% in asthmatics not taking ICS [12]. Of the 196 sub-
jects classified as asthmatic by a clinician and who were
negative to mannitol, 81% (n = 159) were taking ICS.
Table 5: Vital signs at baseline (before pre challenge spirometry), and the change (∆) at end of challenge and during recovery for the 
safety population
Parameter Challenge Point Mannitol Hypertonic Saline
n 627 636
Heart Rate (beats/ minute) Baseline 75.9 ± 13.4 76.2 ± 13.6
End Challenge ∆7.2 ± 10.8 ∆5.4 ± 9.2
Recovery to pre Challenge FEV1 or 15 min post Challenge ∆1.6 ± 10.0 ∆0.7 ± 9.3
Respiration Rate (per min) Baseline 17.1 ± 4.3 17.1 ± 4.3
End Challenge ∆1.0 ± 3.3 ∆1.1 ± 3.7
Recovery to pre Challenge FEV1 or 15 min post Challenge ∆0.1 ± 2.9 ∆0.2 ± 3.0
Systolic Blood Pressure Baseline 117.0 ± 14.8 116.9 ± 14.6
mm Hg End Challenge ∆1.5 ± 9.5 ∆1.5 ± 9.2
Recovery to pre Challenge FEV1 or 15 min post Challenge ∆-0.1 ± 8.8 ∆0.5 ± 9.1
Diastolic Blood Pressure Baseline 72.0 ± 10.0 72.6 ± 10.2
mmHg End Challenge ∆2.4 ± 7.5 ∆1.7 ± 7.4
Recovery to pre Challenge FEV1 or 15 min post Challenge ∆1.2 ± 7.0 ∆0.4 ± 7.3
% oxygen saturation by Baseline 97.2 ± 1.8 97.5 ± 1.6
pulse oximeter End Challenge ∆0.8 ± 2.0 ∆-0.7 ± 1.9
Recovery to pre Challenge FEV1 or 15 min post Challenge ∆-0.4 ± 1.6 ∆-0.1.4 ± 1.6
Table 6: The incidence of respiratory symptoms as reported by symptom diary during 7 days following challenge for the safety 
population
Symptom / beta2agonist use Mannitol Hypertonic Saline
n 627 (%) 636 (%)
Daytime cough 352 (56.9) 365 (58.4)
Wheeze 270 (43.6) 280 (44.8)
Trouble breathing 270 (43.6) 262 (41.9)
Symptoms interfering with activities 172 (27.8) 178 (27.4)
Night time cough 212 (34.2) 236 (37.8)
Beta2 agonist use 319 (51.5) 333 (53.3)
Nebulised beta2 agonist 16 (2.6) 19 (3.0)Respiratory Research 2005, 6:144 http://respiratory-research.com/content/6/1/144
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These subjects represented 33% of the 487 diagnosed
asthmatic subjects. Re-analysis of the data after exclusion
of this group showed a sensitivity of 88.7% for mannitol
to identify a clinical diagnosis. This value is more consist-
ent with findings in earlier studies. It should be noted
however that use of the mannitol challenge for diagnostic
purposes in subjects taking ICS warrants caution in the
interpretation of a negative test result.
Koskela et al [18] have suggested that "if mannitol is used
to monitor effect of ICS in asthma, the goal of treatment
should be unresponsiveness". Further, Leuppi et al have
used a negative test as a starting point for back titration of
steroids [19]. Thus for those 70.1% of asthmatics taking
ICS with a positive response to mannitol, the dose of ICS
may have been inadequate and/or the compliance with its
use poor so that the airway inflammation was still active.
In conclusion the mannitol challenge was generally safe
and well tolerated. No serious adverse events were
recorded. Mannitol PD15 had a sensitivity of 81% and spe-
cificity of 87% with respect to PD15 for 4.5% saline. A pos-
itive mannitol test cut off of a 15% fall in FEV1 (PD15)
provided appropriate sensitivity and specificity with
respect to clinical diagnosis of asthma even when the
patient's baseline FEV1  was within the normal range.
Based on an analysis of patients with a clinical diagnosis
of asthma, and excluding those with a negative test result
and on current corticosteroid therapy, mannitol PD15 had
a sensitivity of up to 89% to detect the presence of asthma
and specificity of 95% for clinical diagnosis of asthma.
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